1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,378 | 0,441 | 13:06 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Mauna Kea Technologies Announces 9 Presentations Demonstrating the Clinical Value of Cellvizio at Digestive Disease Week 2024 | 203 | Business Wire | AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology's largest international meeting
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2023 Annual Financial Report | 205 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform... ► Artikel lesen | |
| 29.04. | Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics | 176 | Business Wire | Cellvizio utilization continues to expand globally in established and emerging clinical indications
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor... ► Artikel lesen | |
| 25.04. | Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales | 268 | Business Wire | Full Year 2023 Sales increased +42%1 to €10.5m €1.2m positive full-year operating income +47% growth in Q1 2024 in U.S. PPU volume Recent Telix strategic investment and restructured EIB... ► Artikel lesen | |
| 24.04. | Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank | 259 | Business Wire | Renewed EIB confidence in Mauna Kea extending support until 2029 Final maturities deferred 4 years to 2028 and 2029 Alignment of debt maturities with the Group's trajectory of profitability... ► Artikel lesen | |
| 04.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 187 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 02.04. | Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio to Identify and Treat Food Intolerance in Adults | 274 | Business Wire | Italy becomes the third country to launch a Cellvizio Center of Excellence following the Metrodora Institute in the U.S. and several other centers in Germany Another key milestone in a global... ► Artikel lesen | |
| 27.03. | Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio | 292 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and V7... ► Artikel lesen | |
| 06.03. | Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio to Identify and Treat Food Intolerance in Adults | 238 | Business Wire | Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from Irritable Bowel Syndrome (IBS) Metrodora will... ► Artikel lesen | |
| 05.03. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 189 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 07.02. | Mauna Kea Technologies Welcomes Benoit Chardon as Senior Advisor to Scale its Irritable Bowel Syndrome and Food Intolerance Business | 287 | Business Wire | Mr. Chardon is a recognized commercialization expert with a successful track record in new category creation in the health wellness industry
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen | |
| 05.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 368 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT)
Listing: Euronext Growth Paris
ISIN code:... ► Artikel lesen | |
| 01.02. | Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate | 292 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces... ► Artikel lesen | |
| 31.01. | MAUNA KEA TECHNOLOGIES: Half-Year Liquidity Contract Statement for H2 2023 with the Brokerage Firm Gilbert Dupont | 315 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 25.01. | Mauna Kea Technologies Reports Full Year 2023 Sales of €10.5m, Up +42%1 vs 2022 | 551 | Business Wire | PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy... ► Artikel lesen | |
| 08.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 298 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT)
Listing: Euronext Growth Paris
ISIN code:... ► Artikel lesen | |
| 05.12.23 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 238 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 13.11.23 | Telix Pharmaceuticals Limited: Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery | 489 | PR Newswire | MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Paris-based Mauna Kea Technologies (Euronext Growth: ALMKT,... ► Artikel lesen | |
| 13.11.23 | Mauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic Surgery | 530 | Business Wire | Builds on existing research collaboration for precision surgery in urology Telix Pharmaceuticals to acquire a ~19% stake in Mauna Kea Technologies through a €6 million equity investment
Regulatory... ► Artikel lesen | |
| 06.11.23 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 335 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website:... ► Artikel lesen |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA | 0,269 | +9,08 % | Sernova gibt organisatorisches Update bekannt | - Dr. Philip Toleikis geht zum 30. April 2024 in den Ruhestand
- Kosteneinsparungen durch Umstrukturierung und strategische Transformation werden voraussichtlich den Cash... ► Artikel lesen | |
| VITA 34 | 4,660 | 0,00 % | EQS-News: Vita 34 AG: Vita 34 kehrt 2023 auf Wachstumspfad zurück | EQS-News: Vita 34 AG
/ Schlagwort(e): Jahresergebnis
Vita 34 kehrt 2023 auf Wachstumspfad zurück
30.04.2024 / 22:51 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| GERATHERM MEDICAL | 4,500 | -0,88 % | Geratherm Medical AG: Geratherm meldet Kurzarbeit an; Kursziel gesenkt; mwb research bekräftigt KAUFEN | Geratherm hat angekündigt, im Werk Geratal Kurzarbeit zu beantragen, weil der Absatz von Fieberthermometern aufgrund des milden Winters unter Plan lag. Der Anteil der Fieberthermometer am Gesamtumsatz... ► Artikel lesen | |
| PLUS THERAPEUTICS | 2,115 | +3,17 % | Plus Therapeutics Inc.: Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial | Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, "CNSide" and discussed potential partnering opportunities CNSide can significantly improve LM diagnostic... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,568 | -0,88 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines | ||
| MEDICLIN | 2,900 | 0,00 % | Mediclin: Gewinnerwartungen werden verändert | Bei Mediclin steigt der Umsatz im ersten Quartal um fast 5 Prozent auf 185,4 Millionen Euro an. Das EBIT verbessert sich von -1,7 Millionen Euro auf +4,1 Millionen Euro. Die Kapazitätsauslastung wird... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 0,132 | +3,60 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores | BOULDER, CO / ACCESSWIRE / May 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc.: NovAccess Global Advisory on Annual Meeting of Shareholders | CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its... ► Artikel lesen | |
| REWALK ROBOTICS | 4,675 | 0,00 % | ReWalk Robotics Ltd. (DBA Lifeward): Lifeward to Report First Quarter Financial Results on May 15, 2024 | ||
| VERU | 1,299 | +1,01 % | Veru Inc.: Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program | --Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific... ► Artikel lesen | |
| DIASORIN | 93,58 | +0,26 % | Barclays cites DiaSorin's in-line top-line but 'ambitious' margins - starts at 'equal weight' | ||
| RXSIGHT | 61,40 | 0,00 % | Why RxSight (RXST) Shares Are Falling | ||
| FRESENIUS | 28,610 | +2,07 % | Fresenius: Schöner Aufwärtstrend! | Der RuMaS Express-Service und die RuMaS Trading-Tipps bieten für Anfänger, erfahrene Anleger und Vieltrader gleichermaßen ein breites und qualitativ ausgezeichnetes Angebot an Börsentipps. Für Börsenneulinge... ► Artikel lesen | |
| PROGYNY | 32,500 | 0,00 % | Progyny falls on dour Q2, annual revenue forecast |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,378 Euro und damit +0,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
